Press Releases

26 September 2019

Acacia Pharma Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020

05 September 2019

Interim Results for the Six Months ended 30 June 2019

18 July 2019

Founder Dr. Julian Gilbert steps down - Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession

12 July 2019

Editorial on Positive Data for BARHEMSYS® Treatment of PONV Published in Anesthesia & Analgesia

08 July 2019

Acacia Pharma Plans to Resubmit the BARHEMSYS® NDA in Q3 2019

03 June 2019

Annual General Meeting Results and Statement

10 May 2019

Acacia Pharma’s BARHEMSYS® Significantly Improves Post-operative Nausea & Vomiting (PONV) in Rescue Treatment of Ambulatory Patients

07 May 2019

Notice of Annual General Meeting

03 May 2019

Acacia Pharma Receives Complete Response Letter from FDA for BARHEMSYS®

25 April 2019

Positive Phase 3 BARHEMSYS® Rescue Treatment Data to be Presented at the Annual Congress of Enhanced Recovery and Perioperative Medicine

27 February 2019

Results for the year ended 31 December 2018

28 January 2019

Editorial in Anesthesiology on Positive Data for BARHEMSYS™ PONV Rescue Treatment

22 January 2019

Supportive Cardiac Safety Data for BARHEMSYS™

12 December 2018

Positive Clinical Results for APD403 in CINV Published in Supportive Care in Cancer

07 December 2018

New BARHEMSYS™ PDUFA date confirmed for 5 May 2019

21 November 2018

Positive BARHEMSYS™ Rescue Treatment Data Published in Anesthesiology

06 November 2018

Acacia Pharma Resubmits BARHEMSYS™ New Drug Application

06 November 2018

Unaudited Results for the nine months to 30 September 2018

15 October 2018

Further update on FDA regulatory review of BARHEMSYS™ 

08 October 2018

Update on FDA regulatory review of BARHEMSYS™

14 September 2018

Positive BARHEMSYS™ Phase 3 Treatment Data Published in Anesthesia & Analgesia

07 September 2018

Interim Results for the First Half Year 2018

09 July 2018

Operating Update for the First Half 2018

02 July 2018

$30 Million Credit Facility with Hercules Technology Growth Capital Secured to Support Intended Commercialisation of BARHEMSYS™ in the US

11 April 2018

US Commercial Operations for BARHEMSYS™ (formerly BAREMSIS®) Expanded Four Key Appointments